Provided are insights from previous research projects:
1. Hepatitis
2. Pancreatic cancer
3. Migraine
4. Insomnia
5. Erectil dysfunction (ED)
1. Hepatitis
Effective November 1, 2000 the Japanese Ministry of Health, Labor
and Welfare created a special "Hepatitis Task Force". The prime
objective of the joint task force is to generate policy and
practical measures to counteract the growing number of HBV (1
million) and HCV (2 million) cases in Japan, and the highest in the
world mortality rate of liver cancer. One of the main implications
of the new policy will be the approval of new and advanced therapies
still not available in Japan.
2.
Pancreatic Cancer
For the past twenty years the malignant neoplasia have been the
leading cause of death in Japan, and with 17,000 cases annually the
pancreatic cancer is the fifth leading cause of cancer death. The
classification of pancreatic tumors adopted in Japan differs from
UICC system and along with comprehensive surgical approaches creates
a significant market opportunities.
Read more in related report
3.
Migraine Recent
simultaneous launch of two major products for treatment of migraine
- Imigran (Sumatriptan succinate) Tablets 50 mg by GlaxoSmithKline
KK and Zomig (Zolmitriptan) Tablets 2.5 mg by AstraZeneca KK signify
the potential of the Japanese headache market. Around 8.4 million
people in Japan are estimated to suffer from migraine or other forms
of headache.
Read more in related report
4. Insomnia
Insomnia and its forms - similarly to all other conditions and
disorders related to the mental activities, are difficult to
approach and study in Japan. Cultural layers, controversies and
still poorly understood patterns in the patients behavior all
contribute to making the research on insomnia one of the most
complicated projects in medical and pharmaceutical market research.
Read more in Licenscape publication
5. Erectile dysfunction
Vendors estimations put the number of ED sufferers in Japan to be
more than 1.1 million men in Japan, yet the actual figures of sales
of the only two registered products - sildenafil (marketed under the
brand of Viagra) and vardenafil (marketed under the brand of Levitra), suggest considerably lower number of patients taking the PDE-5 inhibitors.
Read more in related report
|